Fenergan

Quick links to important sections

Fenergan

Selected form

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fenergan

What is Fenergan? (Promethazine)

Property Description
Active ingredient Promethazine hydrochloride (INN)
Forms Tablet, Syrup, Suppository, Injectable solution
Pharmacological class First-Generation H₁-Antihistamine, Antiemetic
Common purpose Managing allergic symptoms, inducing sedation, preventing nausea
Origin Synthetic Phenothiazine derivative

What is Promethazine and What Type of Drug is Fenergan?

The medication Fenergan is the trade name for the active substance Promethazine hydrochloride, a potent, chemically synthesized compound. It is formally classified as a first-generation H1-antihistamine and belongs to the larger chemical class of Phenothiazine derivatives. Fenergan is often a prescription-only medicine (Rx) in many jurisdictions, reflecting the necessity for professional oversight due to its significant central nervous system (CNS) effects.

Promethazine's identity as a first-generation agent is specifically defined by its ability to readily cross the blood-brain barrier (BBB), which distinguishes it from newer, less-sedating anti-allergic agents. This BBB penetration grants the drug significant activity within the CNS. Promethazine's structure facilitates simultaneous H1 blockade and CNS action. This characteristic is responsible for its dual effects as both an anti-allergy agent and a significant sedative, making it clinically recognized for use in situations requiring deep rest or pre-procedural calming.

Composition, Origin, and Available Forms

Fenergan is primarily a single-active-ingredient product, consisting of Promethazine hydrochloride, which is a synthetic compound derived from the Phenothiazine chemical structure.

This medication is manufactured to facilitate flexible delivery for different patient needs. The common dosage forms include oral options such as tablets and liquid syrup or solution. For specialized or severe needs, it is also prepared as rectal suppositories and a sterile solution for injection suitable for both intramuscular (IM) and intravenous (IV) route of administration. Its strong antiemetic property makes it particularly useful in these non-oral forms for managing severe vomiting, offering a significant differentiating factor compared to oral-only antihistamines.

What is the General Purpose of Promethazine?

The general purpose of Promethazine is defined by its ability to provide relief across three distinct symptomatic domains: managing allergic response, inducing sedation, and controlling nausea.

This utility stems from its strong blockade of histamine receptors to manage general allergic symptoms such as itching; its depressive effect on the CNS, which is leveraged to induce sedation or serve as a sleep aid; and its specific influence on brain signals which makes it effective as an antiemetic agent for preventing or controlling various types of nausea and vomiting. A typical use scenario involves its application for controlling motion sickness, a common indication supported by decades of clinical experience.

Regulatory References

  1. Promethazine Mechanism of Action (NIH/NCBI)

What side effects are possible with Fenergan?

Possible Side Effects and Safety Information

Fenergan's safety profile is officially characterized by effects on the Central Nervous System (CNS) and anticholinergic activity, as detailed in government regulatory documents like the FDA Prescribing Information and the SmPC.

Adverse Reaction Scope and Classification

Adverse reactions are classified by frequency and system-organ class:

Classification/System Documented Effects
Common (CNS/Anticholinergic) Sedation (drowsiness), dizziness, dry mouth, blurred vision, and headache. Sedation is typically most pronounced at the start of therapy.
Serious / Rare (Hematologic/Systemic) Agranulocytosis (severe reduction in white blood cells), jaundice (cholestatic), photosensitivity, and seizures (convulsions).
Serious / Life-Threatening Fatal respiratory depression in very young children and Neuroleptic Malignant Syndrome (NMS), a rare but severe reaction.

Safety Restrictions and Special Populations

  • Pediatric Contraindication: Fenergan is contraindicated for use in children less than 2 years of age due to the potential for fatal respiratory depression. Caution is advised for children 2 years of age and older.
  • Older Adults: Geriatric patients may be more susceptible to dizziness, confusion, and severe anticholinergic effects (e.g., urinary retention, constipation).
  • Specific Limitations: The drug is contraindicated in patients with a comatose state, those with compromised respiratory function (e.g., asthma, COPD), and for specific routes of injection (intra-arterial and subcutaneous) due to the risk of severe tissue damage.

These classifications and constraints establish the medicine’s risk boundaries as defined by health authorities, with the primary concerns focused on CNS depression and specific contraindications for vulnerable populations.

Overdose and Emergency Response

Overdose and when to seek help

Overdose with Promethazine (Fenergan) is defined by severe and potentially life-threatening systemic effects, according to official regulatory documentation.

Overdose Scope Documented Regulatory Statements
Documented Manifestations: Symptoms include central nervous system (CNS) effects, ranging from somnolence and coma to agitation, hallucinations, and seizures. Anticholinergic signs such as hyperpyrexia (fever), dilated pupils, and urinary retention are also documented.
Severe Outcomes: Officially listed risks include fatal respiratory depression, which is a primary concern in pediatric patients, and the potential for sudden death. Life-threatening neurological emergencies like Neuroleptic Malignant Syndrome (NMS) and cardiovascular effects such as arrhythmias and hypotension are also cited.
Population-Specific Note: The medication is contraindicated for use in children under two years of age due to the explicit risk of fatal respiratory depression. Elderly patients are noted to be particularly susceptible to confusion and anticholinergic effects.
Emergency Actions Regulator-Mandated Action
Urgent Help Required: Seek immediate medical attention for any suspected overdose. Immediately call emergency services if the person has collapsed, had a seizure, has trouble breathing, or cannot be awakened.
Management: Management is symptomatic and supportive. There is no specific antidote. Treatment may involve airway support, monitoring of vital signs, and an ECG. Regulatory information explicitly states that epinephrine should NOT be used to treat associated hypotension.

Therapeutic Uses of Fenergan

What Fenergan Treats: Main Uses and Benefits

Fenergan (promethazine) is commonly used across conditions presenting with episodic or fluctuating manifestations where supportive symptom management is appropriate. It is considered relevant for addressing several key symptom domains, which may provide support that helps ease the overall symptom burden.

The medication is used for allergies, feeling and being sick (vomiting), and as a sedative. These uses are aligned with standard therapeutic applications.

The medication is applied to address symptom clusters that may become intense or disruptive, including symptoms related to physical discomfort, systemic imbalance, and neurological activity. It assists with maintaining functional stability during episodes of heightened discomfort from stomach distress or allergic reactions.

“Fenergan is applied in scenarios where additional management of discomfort is required for symptoms related to systemic imbalance.”

It is commonly used to help with symptoms that create noticeable functional strain, which supports general well-being during symptomatic phases.

Quick Fact: Relief for Allergic, Nauseous, and Nervous Symptoms

Eligibility and Restrictions for Use

The official eligibility profile for Fenergan (promethazine) is strictly defined by regulatory guidelines due to its effects on the central nervous system (CNS) and potential to cause respiratory depression.

Fenergan is strictly contraindicated in all pediatric patients less than two years of age due to the potential for fatal respiratory depression. The medicine must not be used by individuals in a comatose state, those with known hypersensitivity to promethazine, or patients being treated for lower respiratory tract symptoms, including asthma.

Use requires professional caution in specific populations. This includes patients with impaired liver function, pre-existing seizure disorders (as the drug may lower the seizure threshold), and patients with conditions like narrow-angle glaucoma. It is not recommended for patients with already compromised respiratory function or for children displaying signs of Reye’s syndrome. For older adults, dose selection must be cautious, typically starting at the low end of the dosing range. Caution is also advised during pregnancy and breastfeeding.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

This section summarizes officially documented interaction patterns for Promethazine (Fenergan) as detailed in regulatory prescribing information.

Contraindicated Combinations

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is formally prohibited and must be avoided for 14 days following MAOI discontinuation. Additionally, combinations with other medicinal products known to prolong the QTc interval (e.g., Pimozide, Thioridazine) are contraindicated due to the risk of additive cardiac effects. In children under 2 years of age, Promethazine is contraindicated due to the heightened risk of fatal respiratory depression, particularly with other respiratory depressants.

Pharmacodynamic and Metabolic Interactions

Promethazine may increase, prolong, or intensify the sedative action of alcohol and other Central Nervous System (CNS) depressants (e.g., opioids, hypnotics), resulting in an additive CNS depression. Promethazine has the potential to reverse the vasopressor effect of Epinephrine; therefore, Epinephrine should not be used to treat promethazine-associated hypotension. Metabolically, Promethazine is primarily processed by the CYP2D6 enzyme. Co-administration with known CYP2D6 inhibitors can formally increase promethazine plasma concentration by reducing its clearance.

Timing and Procedural Constraints

Promethazine must be discontinued at least 72 hours before allergen skin testing to prevent inhibition of the histamine response. Additionally, co-administration with the contrast agent Metrizamide requires that phenothiazine derivatives be discontinued 24 hours before its use.

Mechanism of Action

Fenergan, an identity of promethazine, exerts its primary pharmacologic actions through non-selective receptor antagonism across the central nervous system (CNS) and peripheral tissues. Its key biological target is the histamine H1 receptor, a G protein-coupled receptor (GPCR). Promethazine acts as a competitive inverse agonist/neutral antagonist at this receptor, thereby stabilizing it in an inactive conformation and preventing the binding and activity of endogenous histamine.

Beyond H1 antagonism, promethazine also demonstrates significant antagonism at muscarinic acetylcholine receptors (M1, M2, M3, M4, M5), and dopamine D2 receptors. Antagonism of muscarinic acetylcholine receptors in the CNS and periphery disrupts parasympathetic cholinergic signaling, leading to widespread anticholinergic effects. Dopamine D2 receptor antagonism occurs primarily within the mesolimbic and tuberoinfundibular pathways. The modulation of multiple GPCR signaling pathways results in system-level physiological consequences, including general CNS depression and decreased smooth muscle contraction in various organ systems, which contributes to overall functional suppression across diverse physiologic systems.

Dosage and Administration Information

The administration of Fenergan (promethazine hydrochloride) involves specific routes, dosing principles, and conditions for use. The medication is available for oral use (tablets and syrup), rectal use (suppositories), and parenteral use as a sterile solution for intramuscular (IM) or intravenous (IV) injection.

Dosing is tailored to the intended administration scenario. For oral use in managing allergic conditions, the typical adult range is 12.5 mg to 25 mg per dose, often taken in divided doses or as a single dose at bedtime. When used for short-term sedation, a higher single dose, usually 25 mg to 50 mg, is commonly administered once daily at bedtime or before a procedure. The total daily oral intake is generally limited and typically does not exceed 100 mg.

Specific procedural rules govern administration and timing. Oral forms may be taken with food or milk to reduce potential gastric irritation. For injection, the IM route is preferred over the IV route. If the IV route is utilized, the solution is administered slowly, at a rate not exceeding 25 mg per minute, and must be diluted to a concentration not exceeding 25 mg per milliliter before injection. For older adults and pediatric patients, the lowest effective dose is utilized for managing symptoms.

Administration Condition Instruction
Oral Intake May be taken with food, water, or milk.
IV Rate/Concentration Must not exceed 25 mg/ min or 25 mg/ mL.
Motion Sickness Timing Initial dose 30 to 60 minutes before travel.
Parenteral Restriction IM route is preferred; Intra-arterial or subcutaneous injection is prohibited.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Fenergan

Overview of Clinical Studies

Research examined Promethazine for three primary indications: episodic allergic manifestations, prevention of nausea and vomiting, and temporary sedation for procedures. The evidence base includes regulatory reliance documentation and comparative clinical trials, with Randomized Controlled Trials (RCTs) used particularly for antiemetic research in perioperative settings. Studies monitored outcomes like the suppression of the wheal and flare response in allergy studies, and changes in the incidence of nausea episodes. These findings describe patterns observed over short-term periods following administration.

Evidence in Specific Contexts

Studies were evaluated in diverse populations, including adults, children 2 years of age and older, and patients in obstetric settings for sedation during labor. For antiemetic use, research shows patterns related to dose-limiting factors; the prominent sedative characteristic was associated with variability in outcomes when studied alongside pain medication. Research for its use as a general sleep aid shows low certainty because evidence is limited for managing primary chronic insomnia.

Limitations and Research Gaps

A significant limitation is the reliance on historical evidence for regulatory approval in some indications, meaning the primary data may not meet the methodological standards of modern RCTs. The follow-up durations were limited in most key trials, often spanning 4 to 12 hours of observation. Consequently, there is limited information for long-term outcomes, and the research does not determine the durability of effects over extended use periods. Data for certain groups remain insufficient, and comparative evidence is lacking against many of the newer, targeted medications now available.

Key Studies & References

  1. Promethazine in the treatment of postoperative nausea and vomiting: a systematic review
  2. A Comparison of Two Differing Doses of Promethazine for the Treatment of Postoperative Nausea and Vomiting
  3. First-generation antihistamines for motion sickness prophylaxis: A Cochrane systematic review summary
  4. Promethazine for Anxiety: Benefits, Side Effects, and Interactions (Review of Sedation/Apprehension Use)

Frequently Asked Questions (FAQ)

Common questions about Fenergan (FAQ)


Q: How does the active ingredient in Fenergan work to stop feelings of nausea and vomiting?

A: Promethazine’s effects are achieved by acting on specific chemical messengers in the central nervous system. Official documents explain that it acts on receptors in areas of the brain that control nausea. This action contributes to its classification as an antiemetic, which helps to control feelings of nausea and vomiting.


Q: Is Fenergan used for both short-term relief and longer-term use?

A: According to official guidance, Fenergan is intended for short-term use. Regulatory documents state that the medication should generally not be taken continuously for longer than 7 days without seeking professional evaluation regarding the continued necessity of the medication.


Q: What is the difference between Fenergan tablets, syrup, and suppository forms?

A: Fenergan is available in several forms, including tablets, liquid syrup, rectal suppositories, and a sterile solution for injection. The non-oral forms, such as suppositories, are often used in clinical settings when the severity of vomiting prevents a patient from being able to take the medication by mouth.


Q: How quickly does the sedative effect of Fenergan typically begin to work?

A: Official product information indicates that the clinical effects, including sedation, are typically apparent fairly quickly. For instance, effects from the oral medication are generally seen within 20 minutes, while injectable forms may act even faster.


Q: What is the typical duration of the anti-nausea effect of Fenergan?

A: The duration of the clinical effects is known to vary among individuals. Regulatory information states that the effects generally last for four to six hours but may persist in some people for up to 12 hours.


Q: Is it normal to feel drowsy the morning after taking Fenergan for sleep?

A: Yes, drowsiness is a common and expected effect of the medication. Official warnings indicate that even when taken at bedtime, the sedative effects may cause some individuals to feel drowsy or less alert upon arising the next day. This lingering effect is sometimes described as a hangover effect.


Q: How long does the active substance from Fenergan stay in the body?

A: Promethazine stays in the body for a period of time after the effects wear off. The elimination half-life is documented as approximately 10 to 19 hours. This means it generally takes about two to four days for the medication to be fully eliminated from the body.


Q: Can Fenergan cause a paradoxical reaction like feeling restless or excited?

A: Yes, regulatory documents note that paradoxical reactions have been reported, particularly in children. These reactions may include feeling restless, excited, or hyperexcitable. Children are noted as being more likely to experience side effects such as feeling restless or excited.


Q: What is the recommended short-term duration for Fenergan use as a sedative?

A: For use as a sedative, the official guidance is that the medication should generally not be taken continuously for longer than 7 days without seeking professional evaluation regarding its continued use.


Q: Is there a risk of developing nightmares or hallucinations while taking Fenergan?

A: Official product information indicates that hallucinations and nightmares have been reported as adverse reactions. Nightmares are also noted as a possible symptom associated with paradoxical reactions to the medicine.


Q: What are the signs of a serious or severe reaction to Fenergan?

A: Regulatory warnings identify certain signs as needing prompt medical evaluation. These may include yellowing of the skin or eyes (jaundice), which may indicate liver problems; bruising or bleeding more than normal; or a very fast, pounding, or irregular heartbeat.


Q: Is it possible for Fenergan to cause unusual muscle stiffness or movements?

A: Yes, the medication can rarely cause extrapyramidal symptoms. These types of reactions may involve muscle spasms, unusual tic-like movements of the head and face, or muscle stiffness. Official documents suggest these signs warrant prompt medical evaluation.


Q: What are the symptoms of potential liver problems related to Fenergan use?

A: According to official safety information, a sign of potential liver problems is the presence of jaundice. This is when the whites of the eyes or the skin start to turn yellow, and this symptom warrants prompt medical evaluation.


Q: What is Neuroleptic Malignant Syndrome, and is it a documented risk for Fenergan?

A: Neuroleptic Malignant Syndrome (NMS) is a rare but serious reaction that has been reported with Fenergan. Symptoms of NMS include a high fever, severe muscle rigidity, and altered mental status. Official safety warnings indicate that an irregular pulse or blood pressure can also occur.


Q: What is the safety guidance for children 2 years of age and older taking Fenergan?

A: For children 2 years of age and older, official regulatory guidance advises caution due to the potential for serious respiratory depression. The guidance emphasizes the importance of using the lowest effective dose to help manage symptoms in this age group.


Q: Is it safe to take Fenergan with common over-the-counter painkillers like ibuprofen or paracetamol?

A: Official guidance suggests that taking Fenergan with common non-opioid painkillers, such as paracetamol or ibuprofen, is generally safe. However, caution is advised regarding checking the ingredients of any cold or pain remedies to help prevent accidental overdose of paracetamol.


Q: What are the precautions necessary for people who drive or operate machinery while taking Fenergan?

A: Due to its sedative nature, official warnings state that Promethazine may impair the mental and physical abilities required for performing hazardous tasks. This includes driving a vehicle or operating machinery. Official guidance suggests individuals should avoid engaging in these activities until they are certain how the medication affects them.


Q: Does Fenergan contain codeine or any other controlled substances?

A: Promethazine hydrochloride (Fenergan) as a single ingredient medication does not contain codeine and is not classified as a controlled substance. However, some combination products that contain promethazine, such as those with codeine, are classified as controlled substances.


Q: Can Fenergan affect the reliability of certain home pregnancy tests?

A: Yes, official warnings indicate that Promethazine may interfere with immunological urine pregnancy tests. This interference can potentially lead to either false-positive or false-negative results. If a person suspects they are pregnant, consulting a healthcare provider for definitive testing is recommended.

How should Fenergan be stored and disposed of?

How to Store and Dispose of Fenergan

Fenergan (promethazine hydrochloride) must be stored and disposed of according to specific regulatory mandates to maintain its stability and ensure safety.

Requirement Storage Condition
Temperature (Oral Forms) Controlled Room Temperature: 20^circ to 25 C (68^circ to 77 F), avoiding freezing.
Temperature (Suppositories) Store in the refrigerator.
Protection Store in a tight, light-resistant container; protect from excess heat and moisture.
Stability Discard the injection solution if color or particulate matter is observed.

All forms of Fenergan must be stored out of the reach of children. For disposal, unused or expired medicine should be returned via a drug take-back program. Any associated sharps from the injectable form must be placed in an FDA-cleared sharps disposal container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Fenergan found in:

A-Z Index: